Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study

Area of Science:

• Neuroscience
• Pediatric Medicine
• Pharmacology

Background:

• Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral disorder in school-aged children.
• Existing treatments for ADHD may be ineffective or cause adverse effects in some patients.
• Citicoline, an endogenous molecule, shows potential for improving attention, impulsivity, and memory.

Purpose of the Study:

• To evaluate the efficacy and safety of citicoline as a treatment for pediatric ADHD.
• To compare the effects of citicoline versus placebo in children diagnosed with ADHD.

Main Methods:

• A randomized, crossover, double-blind, placebo-controlled clinical trial was conducted.
• Participants were children aged 7-12 years diagnosed with ADHD.
• The study assessed various parameters to determine treatment effects.

Main Results:

• No statistically significant differences were observed between citicoline and placebo groups for the evaluated parameters.
• Citicoline treatment was found to be safe and well-tolerated, with no reported adverse effects.
• The study did not find evidence of citicoline's efficacy in treating ADHD in this pediatric population.

Conclusions:

• Citicoline appears to be a safe supplement for pediatric use.
• Further research is needed to fully understand the therapeutic potential of citicoline for ADHD.
• Current findings suggest citicoline is not an effective treatment for ADHD based on the evaluated parameters.